The equity financing was co-led by new investor, Abingworth, and current investor, MPM Capital, and also included investments from existing shareholders, 7...
You must be logged in to view the whole article.
Click here if you require signing up
Astellas, Medivation seek Japanese nod for enzalutamide for prostate cancer
Norgine's Xifaxan 550 mg gets PBAC recommendation for hepatic encephalopathy
Merrimack finalises enrolment in Phase II study of MM-121 plus exemestane in breast cancer
R-Tech Ueno starts patient enrolment in Phase I/II severe dry eye
Steribeam announces results of six logs sterilisation of B pumilus spores
AbbVie starts Phase 3 study of atrasentan in diabetic nephropathy patients
GlaxoSmithKline plans to close tablet-packaging facility in Melbourne
Jennerex Biotherapeutics completes enrolment of 120 patients in Phase 2b trial of Pexa-Vec